Sebacia, Inc., a Duluth, Ga.-based clinical and commercial stage dermatology and aesthetics company, completed a $20m Series D financing and a $16m debt facility.
Backers included existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund and new investors Salem Partners and others. The debt facility was provided by Hercules Capital.
The company intends to use the proceeds to complete a U.S. pivotal trial with expected results reporting by mid-2018, with submission and FDA response expected by the end of 2018, to expand its commercial presence in the European Union and its worldwide patent estate, which includes the seminal selective photothermalysis methods developed by Dr. R. Rox Anderson at Massachusetts General Hospital.
Led by Anthony V. Lando, Chief Executive Officer, Sebacia is developing a proprietary microparticle treatment for moderate to severe acne. Its microparticles are delivered in a topical suspension specifically designed to work with hair removal or pigmented lesion treatment laser systems, which are already owned by the dermatologist. The treatment is intended to be a physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin.
Sebacia has extensive clinical experience with nearly 2,000 treatments performed to date. The procedure is CE Marked in Europe and is being evaluated in clinical studies in the United States.